AORT
HealthcareArtivion, Inc. · Medical - Devices · $1B
What is Artivion, Inc.?
Artivion, Inc. is a small-cap healthcare company focused on aortic and vascular surgery. Headquartered in Kennesaw, Georgia, it manufactures medical devices and processes implantable human tissues distributed to surgeons worldwide.
Artivion generates revenue by selling surgical devices, stent graft systems, and tissue preservation services used primarily in aortic and vascular procedures. Its product lines span open surgical repair, endovascular intervention, and cardiac surgery. The company sells to hospitals and surgical centers globally, with a meaningful portion of revenue coming from international markets. Revenue streams include both device sales and fee-based tissue processing services.
Artivion was founded in 1993 and is headquartered in Kennesaw, Georgia, US.
- BioGlue surgical adhesive for cardiac and vascular procedures
- On-X prosthetic heart valves for aortic and mitral replacement
- E-vita and E-nya thoracic aortic stent graft systems
- Cardiac and vascular tissue preservation services
- PerClot absorbable powdered hemostat for surgical hemostasis
Is AORT a Good Stock to Buy?
UQS Score rates AORT as Below Average overall, reflecting meaningful structural challenges alongside some areas of relative promise.
The Growth pillar stands out as the clearest positive — Artivion has been expanding its product portfolio and international footprint in ways that support a forward-looking revenue trajectory. The Risk pillar lands at Neutral, suggesting the company's risk profile is neither particularly alarming nor especially reassuring relative to sector peers.
Both the Quality and Moat pillars register as Weak, pointing to below-average profitability characteristics and limited durable competitive advantages compared to stronger healthcare device peers.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AORT pay dividends?
No — Artivion, Inc. does not currently pay a dividend.
Artivion does not currently pay a dividend. For a small-cap medical device company still investing heavily in product development and international expansion, retaining capital is a common strategic choice. Investors seeking income from this sector may need to look elsewhere, as AORT's capital allocation appears oriented toward growth reinvestment rather than shareholder distributions.
When does AORT report earnings?
Artivion reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue growth has been a relative bright spot for Artivion, supported by international device sales and expanding adoption of its stent graft portfolio. Profitability, however, remains a work in progress, with the Quality pillar signaling below-average earnings characteristics relative to sector peers.
For the most recent quarter's results and guidance, visit Artivion's investor relations page directly.
AORT Price History
+27.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Artivion, Inc.?
Based on Artivion, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
AORT Long-term Outlook
Artivion's fundamental outlook is shaped by a Good Growth pillar alongside Weak Quality and Moat scores — a combination that suggests revenue expansion potential without yet translating into durable margin strength. The Neutral Risk and Valuation pillars indicate the stock is neither priced at an extreme premium nor carrying outsized financial risk at current levels. Execution on international market penetration and new product launches will likely determine whether growth converts into improved quality metrics over time.
Growth drivers
- International expansion of the aortic stent graft product family
- Growing adoption of minimally invasive endovascular repair procedures
- Broadening cardiac and vascular tissue preservation service volumes
Key risks
- Weak profitability profile limiting financial resilience during downturns
- Limited competitive moat in a market with larger, better-resourced device makers
- Execution risk in integrating product lines and scaling internationally
AORT vs Peers
Artivion operates in a competitive healthcare device landscape alongside companies that address adjacent surgical and implant markets.
AdaptHealth focuses on home medical equipment and respiratory therapy rather than surgical devices, serving a different patient care setting than Artivion.
Establishment Labs specializes in breast aesthetics and reconstruction implants, competing in the implantable device space but targeting a distinct surgical specialty.
Alphatec concentrates on spine surgery solutions, sharing Artivion's small-cap device profile but operating in a separate surgical discipline.
Frequently Asked Questions
What does Artivion do?
Artivion manufactures and distributes medical devices and implantable human tissues used in aortic and vascular surgery. Its products include stent graft systems, prosthetic heart valves, surgical adhesives, and tissue preservation services. The company serves hospitals and surgical centers across multiple continents.
Does AORT pay dividends?
Artivion does not currently pay a dividend. The company appears to prioritize reinvesting capital into product development and international growth rather than returning cash to shareholders through distributions.
When does AORT report earnings?
Artivion follows a standard quarterly earnings reporting schedule. For the exact dates of upcoming earnings releases, check the investor relations section of Artivion's official website, as our data source does not cover specific future dates.
Is AORT a good stock to buy?
UQS Score rates AORT as Below Average overall. The Growth pillar is a relative strength, but Weak Quality and Moat scores indicate structural challenges. Whether it fits your portfolio depends on your risk tolerance and investment goals. View the full pillar breakdown on UQS Pro for a complete picture.
Is AORT overvalued?
The UQS Valuation pillar for AORT is rated Neutral, suggesting the stock is not trading at an obvious extreme relative to its fundamentals. A Neutral valuation label means the current price appears broadly in line with what the underlying business profile supports, though this can shift with market conditions.
How does AORT compare to its competitors?
Artivion is a small-cap aortic device specialist competing in a broader healthcare device landscape. Compared to peers like Alphatec and Establishment Labs, Artivion's focus on aortic and vascular surgery is relatively specialized. Its Below Average UQS Score suggests it lags stronger-rated peers on quality and moat dimensions.
What is AORT's market cap bracket?
Artivion is classified as a small-cap company. This places it in a segment of the market that can offer growth potential but typically carries higher volatility and less financial cushion than large- or mega-cap peers in the healthcare sector.
Who founded Artivion?
Artivion was founded in 1993. The company was originally known as CryoLife before rebranding to Artivion to better reflect its expanded focus on aortic surgery products and technologies. Founding details are widely available through public company records.
Is AORT a long-term quality investment?
As a long-term quality indicator, AORT's Below Average UQS Score — driven by Weak Quality and Moat pillars — suggests the company has not yet established the durable profitability and competitive advantages typically associated with high-quality long-term holdings. The Good Growth pillar offers some forward-looking optimism, but quality consistency matters for long-duration investors.
What is the main competitive advantage of Artivion?
Artivion's competitive positioning centers on its specialized focus in aortic and vascular surgery, a technically demanding niche. Its portfolio of stent graft systems, tissue preservation services, and surgical adhesives creates some product breadth. However, the UQS Moat pillar rates this advantage as Weak relative to sector peers.
What sector does AORT belong to?
Artivion operates in the Healthcare sector, specifically within the medical devices and tissue processing segment. It focuses on aortic and vascular surgical solutions, placing it in a specialized corner of the broader medical device industry.
Unlock Full AORT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access complete financial metrics and trend data
- ✓Compare AORT against sector peers side by side
- ✓See the full analyst-style quality and risk breakdown
- ✓Track score changes over time with Pro alerts
Pro Analysis
AORT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 40.5 | 25.6 | 29.0 | 70.1 | 43.9 | 41.4 | +0.1 |
| May 22, 2026 | 40.4 | 25.5 | 29.0 | 70.1 | 43.9 | 41.3 | -0.2 |
| May 20, 2026 | 40.6 | 25.5 | 29.0 | 70.4 | 43.9 | 41.7 | +0.1 |
| May 19, 2026 | 40.5 | 25.5 | 29.0 | 70.4 | 43.9 | 41.4 | -0.1 |
| May 16, 2026 | 40.6 | 25.5 | 29.0 | 70.4 | 43.9 | 41.7 | -0.2 |
| May 15, 2026 | 40.8 | 25.6 | 29.0 | 70.4 | 43.9 | 43.3 | 0.0 |
| May 14, 2026 | 40.8 | 25.6 | 29.0 | 70.4 | 43.9 | 43.6 | -6.3 |
| May 13, 2026 | 47.1 | 25.1 | 29.0 | 70.4 | 82.9 | 47.0 | +0.1 |
| May 12, 2026 | 47.0 | 25.1 | 29.0 | 70.4 | 82.9 | 46.7 | +0.4 |
| May 11, 2026 | 46.6 | 25.0 | 29.0 | 70.4 | 82.9 | 44.1 | +2.6 |
AORT — Pillar Breakdown
Quality
— 25.6/100 (25%)Artivion, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 70.1/100 (20%)Artivion, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 43.9/100 (15%)Artivion, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 41.4/100 (15%)Artivion, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 29/100 (25%)Artivion, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AORT.
Score Composition
Financial Data
More Stock Analysis
How is the AORT UQS Score Calculated?
The UQS (Unified Quality Score) for Artivion, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Artivion, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Artivion, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.